반응식
[C:1]([O:14][CH2:15][C@H:16]([CH2:31][O:32]P(OCCN)(O)=O)OC(=O)CCCCCCCCCCC)(=O)[CH2:2][CH2:3][CH2:4][CH2:5][CH2:6][CH2:7][CH2:8][CH2:9][CH2:10][CH2:11][CH3:12].CP(CCP(C)C)C.[C:48]([O:63]C[C@H](COP(OCCN)(O)=O)OC(=O)CCCCCCCCCCCCC)(=[O:62])[CH2:49]CCCCCCCCCCCC.[C:91](OC[C@H](COP(OCCN)(O)=O)OC(=O)CCCCCCCCCCCCCCC)(=O)[CH2:92][CH2:93]CCCCCCCCCCCCC.CCN(CC[O:145]C1C=CC(CC2C=CC=CC=2)=CC=1)CC.Cl.C(OC[C@H](COP(OCCN)(O)=O)OC(=O)CCCCCCCCCCCCCCCCC)(=O)CCCCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCCCC(OCC(OC(CCCCCCCCCCCCCCCCC)=O)COP(OCCN)(O)=O)=O>C(Cl)(Cl)Cl.CN(C=O)C>[CH:10]1[CH:11]=[CH:12][C:49]([C:48]([OH:63])=[O:62])=[C:8]([C:7]2[C:6]3[CH:5]=[CH:4][C:3]([OH:145])=[CH:2][C:1]=3[O:14][C:15]3[C:93]=2[CH:92]=[CH:91][C:31]([CH:16]=3)=[O:32])[CH:9]=1참가 물질
10
반응물 7
생성물 1
시약·촉매·용매 2
실험 절차
PE lipids (1,2-dilauroyl-sn-glycero-3-phosphoethanolamine, DMPE; 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, DMPE; 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, DPPE; 1,2-dioctadecanoyl-sn-glycero-3-phosphoethanolamine, DSPE, Avanti polar lipids. Inc.) were dissolved in 500 uL CHCl3 and 500 uL DMF, 1.2 eq of fluorescein-PEG2000-NHS (creative PEG works Inc.) was added and the reaction mixture were agitated overnight, the amphiphilic fluorescein PEG amphiphiles were purified by reverse phase HPLC using a C4 column (BioBasic-4, 200 mm×4.6 mm, Thermo Scientific), 100 mM triethylamine-acetic acid buffer (TEAA, pH 7.5)-methanol (0-30 min, 10-100%) as an eluent.
후처리
- customthe amphiphilic fluorescein PEG amphiphiles were purified by reverse phase HPLC
- customa C4 column (BioBasic-4, 200 mm×4.6 mm, Thermo Scientific), 100 mM triethylamine-acetic acid buffer (TEAA, pH 7.5)-methanol (0-30 min, 10-100%)
출처 및 근거
- ORD 기록
- ord-f710ef369470408c8e0c9f4e03abaeff
- 출처 데이터셋
- uspto-grants-2015_08
- 특허 번호
- US09107904B2
연결된 노트
불러오는 중…